Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2

Citius Pharmaceuticals, Inc.

2025-Q2 EPS reported -$2.79 vs consensus -$0.60 ▼ miss (-363.6%)

Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.
LYMPHIR BLA accepted with PDUFA target date August 13, 2024.
Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.
Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.
Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.

Period: fiscal second quarter 2024 ended March 31, 2024
Net income: Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3
EPS: ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024
Result: reported results

Exact text from the filing

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-042966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.